Clinical Trial Update: TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study of tocilizumab in late/chronic active antibody-mediated rejection after kidney transplantation. The study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Kidney Transplant Rejection

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Vastra Gotaland Region | Conditions: Antibody-mediated Rejection | Phase 3 | Status: RECRUITING